The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.a

Pneumonitis (interstitial lung disease/ILD)

Publications

Zhang J, Liu MH, Gao X, Dong C, Li YX

Vedolizumab-associated diffuse interstitial lung disease in patients with ulcerative colitis: A case report.

World journal of clinical cases 2022 Feb 16;10;1716-1722 — 2022 Feb 16 — 1716-1722

Pugliese D, Privitera G, Schepis T, Larosa L, Onali S, Scaldaferri F, Gasbarrini A, Caprioli F, Armuzzi A

Drug-Related Pneumonitis in Patients Receiving Vedolizumab Therapy for Inflammatory Bowel Disease.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2022 Jun;20;e1483-e1487 — 2022 Jun — e1483-e1487

Lissner D, Glauben R, Allers K, Sonnenberg E, Loddenkemper C, Schneider T, Siegmund B

Pulmonary Manifestation of Crohn's Disease Developed Under Treatment With Vedolizumab.

The American journal of gastroenterology 2018 01;113;146-148 — 2018 01 — 146-148